Pharming Group N.V. (PHAR) Misses Q3 EPS by 0c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PHAR Hot Sheet
Join SI Premium – FREE
Pharming Group N.V. (NASDAQ: PHAR) reported Q3 EPS of $0.00, $0.00 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $74.8 million versus the consensus estimate of $76.93 million.
GUIDANCE:
Pharming Group N.V. sees FY2024 revenue of $280-295 million, versus the consensus of $284.5 million.
For earnings history and earnings-related data on Pharming Group N.V. (PHAR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- ACRES Commercial Realty (ACR) Misses Q3 EPS by 526c
- Relay Therapeutics, Inc. (RLAY) Tops Q3 EPS by 3c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
